- Current report filing (8-K)
January 29 2009 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 29, 2009
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
|
0-19700
(Commission File
Number)
|
|
33-0266089
(I.R.S. Employer
Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CRF 240.13e-4(c))
Item 8.01. Other Events.
On January 29, 2009, Amylin
Pharmaceuticals, Inc. (Amylin) issued a press release confirming that it
has reviewed an amended 13-D filing with the Securities and Exchange Commission
from Amylin shareholder Icahn Capital LP and affiliated funds announcing their
intent to nominate a slate of five directors to stand for election at Amylins
2009 annual meeting. Amylin has not yet
received the required notice with respect to this action.
Amylins Corporate Governance Committee is engaged in a process to
recommend a slate for election at the companys annual meeting. It is reviewing
potential nominees suggested by shareholders as part of that process, including
two individuals previously discussed with representatives of the Icahn funds.
Once the process has been completed, Amylins Board of Directors will formally
recommend a slate of nominees that it believes will act in the best interest of
all shareholders.
A copy of the press release is attached as Exhibit 99.1
and is incorporated herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d)
|
|
Exhibits.
|
|
|
|
|
|
|
|
|
|
Number
|
|
Description
|
|
|
|
|
|
|
|
99.1
|
|
Press release
issued by Amylin on January 29, 2009.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
Dated:
|
January 29,
2009
|
By:
|
/s/
LLOYD A. ROWLAND
|
|
|
|
Lloyd A. Rowland
|
|
|
|
Vice
President, Governance and Compliance, and Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on January 29, 2009.
|
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024